The figure shows cross-sections of mouse hearts with areas of damage in red. Treatment with virus-expressing CRISPR components reduces cardiac damage following ischemic injury.
Editing a gene that prompts a cascade of damage after a heart attack appeared to reverse this inevitable course in mice, leaving their hearts remarkably unharmed, a new study by UT Southwestern scientists showed. The findings, published in Science, could lead to a new strategy for protecting patients from the consequences of heart disease.
“Usually, depriving the heart of oxygen for an extended period, as often happens in a heart attack, will damage it substantially. But those animals whose heart muscles were subjected to gene editing after induced heart attacks seem to be essentially normal in the weeks and months afterward,” said Eric Olson, Ph.D., Director of the Hamon Center for Regenerative Science and Medicine and Chair of Molecular Biology at UTSW, who co-led the study with Rhonda Bassel-Duby, Ph.D., Professor of Molecular Biology.
Since its discovery a decade ago, the CRISPR-Cas9 gene editing system has been used by scientists to correct genetic mutations responsible for disease, including work by the Olson lab on Duchenne muscular dystrophy. However, Dr. Bassel-Duby explained, these diseases caused by mutations affect relatively small groups of people, whereas nongenetic diseases affect far larger numbers. For example, cardiovascular diseases are the leading cause of death globally, killing about 19 million people every year.
Researchers recently discovered that much of the damage from a heart attack – an event characterized by blockage of blood vessels that feed the heart, depriving it of oxygen – is caused by overactivation of a gene called CaMKII?. This gene plays a variety of roles in heart cell signaling and function. The overactivation occurs when the heart is stressed, prompted by oxidation of two methionine amino acids that form part of the CaMKII? protein.
Drs. Olson and Bassel-Duby and their colleagues reasoned that if these methionines could be converted to a different amino acid instead, oxidation wouldn’t occur, sparing the heart from CaMKII? overactivation and subsequent damage after a heart attack.
To test this idea, Simon Lebek, M.D., a postdoctoral fellow, and other members of the team used CRISPR-Cas9 to edit CaMKII? in human heart cells growing in a petri dish. Tests showed that when unedited heart cells were placed into a low-oxygen chamber, they developed numerous markers of damage and subsequently died. However, the edited cells were protected from damage and survived.
The researchers then tried a similar experiment in live mice, inducing a heart attack in these animals by restricting blood flow to their heart’s main pumping chamber for 45 minutes and then delivering CaMKII? gene editing components directly to some animals’ hearts. Both mice that received gene editing and those that did not had severely compromised heart function in the first 24 hours after their heart attacks. But while the mice without the gene editing continued to worsen over time, those that received gene editing steadily improved over the next few weeks, ultimately achieving cardiac function that was nearly indistinguishable from before their heart attacks.
Further research showed that the gene editing appeared to be isolated to the heart – there was no evidence of edited CaMKII? in other organs, including the liver, brain, or muscles. No negative side effects were apparent almost a year out from treatment, Drs. Olson and Bassel-Duby said. The treatment also appeared to be durable, they added, noting that the gene-edited mice were able to do heavy exercise similar to mice that never had heart attacks.
Although this treatment will need substantial safety and efficacy studies before it can be used in humans, the researchers suggest that gene editing could offer a promising solution for treating patients in the aftermath of a heart attack and could have potential for a range of other nongenetic diseases.
Original Article: Gene editing halts damage in mice after heart attacks in UT Southwestern study
More from: University of Texas Southwestern Medical Center
The Latest Updates from Bing News
Go deeper with Bing News on:
- Expert calls for human-controlled evolution to be named 'genetic welding'
Humans are changing evolutionary trajectories via CRISPR tech. Perhaps now is the time to pause and think about what this all actually means.
- Genetic Welding: Unleashing Evolution’s Future or Playing With Ethical Fire?
With CRISPR-Cas9 technology, humans can now rapidly change the evolutionary course of animals or plants by inserting genes that can easily spread through entire populations. Evolutionary geneticist ...
- Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
Vertex Therapeutics VRTX announced that it is entering into a new non-exclusive licensing agreement with CRISPR Therapeutics CRSP for the use of the latter’s gene-editing technology, CRISPR/Cas9. The ...
- Vertex to pay CRISPR $100m to use gene editing tech for diabetes therapy
Vertex will pay CRISPR Therapeutics $100m up-front for non-exclusive rights to its technology with the goal of developing a certain type of therapy for diabetes.
- Up to $230 million or CRISPR Therapeutics
Based on its revolutionary gene editing technology, CRISPR/Cas9, that allows for precise, directed changes to genomic DNA, CRISPR Therapeutics has established a portfolio of therapeutic programs ...
Go deeper with Bing News on:
- Scientists at SKUAST working on gene editing to increase yield of Pashmina wool
Our aim is to just increase the Pashmina wool production and so we have targeted a gene with which we can achieve this, Shah added.Giving the background of the cloning project, Shah said the process ...
- Vertex Pays CRISPR Therapeutics $100M to Bring Gene-Editing to Type 1 Diabetes
Vertex Pharmaceuticals aims to CRISPR Therapeutics’ gene-editing technology to develop type 1 diabetes cell therapies that don’t prompt the immune system to reject them. This approach could compete ...
- KromaTiD Launches dGH in-Site™ CAR-T Kit for TRAC & B2M, Putting Single-Cell Gene Editing Analysis Tech in Customer Hands
KromaTiD Launches dGH in-Site™ CAR-T Kit for TRAC & B2M, Putting Single-Cell Gene Editing Analysis Tech in Customer Hands Mar (PRNewswire ...
- Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology
Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) and gene editing company CRISPR Therapeutics, Inc. (CRSP) announced Monday ...
- Better Beer Through Gene Editing
Using UC Berkley’s own simple and affordable CRISPR-CaS9 gene editing system, researchers [Charles Denby] and [Rachel Li] have edited strains of brewer’s yeast to make it taste like hops.